Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

@article{Fox2008IvabradineFP,
  title={Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial},
  author={Kim Fox and Ian Ford and Philippe Gabriel Steg and Michal Tendera and Roberto Ferrari},
  journal={The Lancet},
  year={2008},
  volume={372},
  pages={807-816}
}

Figures and Tables from this paper

Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
TLDR
It is raised the possibility that ivabradine may be helpful to reduce major cardiovascular events in patients with stable CAD and LVSD who present with limiting angina, however, a large-scale clinical trial is ongoing, which will formally test this hypothesis.
Ivabradine in stable coronary artery disease without clinical heart failure.
TLDR
Among patients who had stable coronary artery disease without clinical heart failure, the addition of ivabradine to standard background therapy to reduce the heart rate did not improve outcomes and was associated with an increase in the incidence of the primary end point among patients with activity-limiting angina but not among those without activity- Limiting Angina.
Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
TLDR
Because of its safety and efficacy to control angina, ivabradine should be considered first-line antianginal treatment in coronary artery disease patients with left ventricular dysfunction and increased heart rate, already receiving beta-blocker therapy or in whom these medications are not tolerated.
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
TLDR
Ivabradine may be important for the improvement of clinical outcomes in patients with LV systolic dysfunction and heart rate ≥ 70 b.p.m., whatever the primary clinical presentation (CAD or HF) or clinical status (NYHA class).
Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study
TLDR
This pilot study shows that intravenous ivabradine may be used safely to slow the heart rate in STEMI and further studies are needed to characterize its effect on infarct size, left ventricular function and clinical outcomes in this population.
Effects of Heart Rate Reduction by Ivabradine for Heart Failure Beyond β-Blockers.
  • Y. Seo, N. Ohte
  • Medicine
    Circulation journal : official journal of the Japanese Circulation Society
  • 2019
ventricULar dysfunction) trial, which consisted of patients with stable coronary artery disease, EF <40%, sinus rhythm, and a resting HR of ≥60 beats/min.3 In the total cohort, no significant
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population
TLDR
Main results from BEAUTIFUL are expected in 2008, and should show whether ivabradine, on top of optimal medical treatment, reduces mortality and cardiovascular events in this population of high-risk patients.
A Single Intravenous Dose of Ivabradine, a Novel If Inhibitor, Lowers Heart Rate but Does Not Depress Left Ventricular Function in Patients with Left Ventricular Dysfunction
TLDR
A single intravenous dose of ivabradine produced a substantial reduction in resting heart rate without affecting LV function in patients with regional or global LV dysfunction.
Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial
TLDR
The results suggest that ivabradine, representing a novel class of antianginal drugs, is effective and safe during 3 months of use; longer-term safety requires additional assessment.
Effect of carvedilol on survival in severe chronic heart failure.
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.
TLDR
High resting heart rate is a predictor for total and cardiovascular mortality independent of other risk factors in patients with stable coronary artery disease, while adjusting for risk factors.
...
1
2
3
4
...